Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 173

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 173
---
, Aadi obtained an exclusive license to WuXi Biologics’ pre-clinical antibody drug conjugate programs targeting Mucin-16 (MUC16), Protein Tyrosine Kinase 7 (PTK7) and Seizure Related 6 Homolog (SEZ6), in each case, leveraging Hangzhou DAC’s linker-payload technology.

License

Under the License Agreement, WuXi
Biologics granted Aadi an exclusive (even as to WuXi Biologics and its affiliates), royalty-bearing, transferable and sublicensable license under certain patents, know-how and other intellectual property to
develop and commercialize certain antibody-drug conjugates targeting each of MUC16, PTK7, and SEZ6 and certain licensed products incorporating such antibody-drug conjugates for any and all indications worldwide. Aadi has agreed to use commercially
reasonable efforts to develop and commercialize licensed product(s) within each ADC Program within certain periods of time and within certain major markets. Aadi may obtain extensions to the certain periods of time in which it must achieve its
diligence obligations as specified in the License Agreement.

Economics

We were required to pay WuXi Biologics an initial upfront payment of $6 million in connection with the execution of the License Agreement. In addition, we
are required to pay WuXi Biologics an additional non-refundable, upfront payment of $38 million within ninety (90) days after execution of the License Agreement, which may be extended by either party
for an additional thirty (30) days.

Pursuant to the License Agreement, WuXi Biologics is eligible to receive from us (a) up to an aggregate of
$265 million upon the achievement of certain development milestones, and (b) up to an aggregate of $540 million upon the achievement of certain commercial milestones, in each case, across all ADC Programs. WuXi Biologics is also
entitled to running royalties during the agreed upon royalty term ranging from low-single-digit to upper-single-digit percentages of annual net sales of licensed products.

Pursuant to the terms of the License Agreement, to the extent any amounts payable under or in connection with the License Agreement are subject to any
value-added tax or indirect tax, such taxes shall be borne and paid by Aadi. The parties, however, are obligated to cooperate with each other to secure any available exemption or reduction in such taxes as specified in the License Agreement.

- 111 -

Royalty Term